ID

38199

Description

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification; ODM derived from: https://clinicaltrials.gov/show/NCT02177175

Link

https://clinicaltrials.gov/show/NCT02177175

Keywords

  1. 9/26/19 9/26/19 -
  2. 9/26/19 9/26/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 26, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Breast Cancer NCT02177175

Eligibility Breast Cancer NCT02177175

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
female
Description

Gender

Data type

boolean

Alias
UMLS CUI [1]
C0079399
age ≥ 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
non-metastatic histologically confirmed primary invasive breast carcinoma
Description

Invasive carcinoma of breast | Neoplasm Metastasis Absent

Data type

boolean

Alias
UMLS CUI [1]
C0853879
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C0332197
pathologically confirmed her2-positive breast cancer
Description

HER2-positive carcinoma of breast

Data type

boolean

Alias
UMLS CUI [1]
C1960398
scheduled to receive anthracycline chemotherapy followed by anti-her2 therapy at mskcc
Description

Chemotherapy Scheduled | Anthracyclines | HER2 Targeted Therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0205539
UMLS CUI [2]
C0282564
UMLS CUI [3,1]
C0069515
UMLS CUI [3,2]
C2985566
able and willing to provide informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
willing and able to comply with the requirements of the protocol
Description

Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1]
C0525058
able to swallow capsules
Description

Able to swallow capsules

Data type

boolean

Alias
UMLS CUI [1,1]
C2712086
UMLS CUI [1,2]
C0006935
for aim 2, all patients must meet the following criteria:
Description

Criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
meet all inclusion criteria above
Description

Inclusion criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C1550543
lvef > 50%
Description

Left ventricular ejection fraction

Data type

boolean

Alias
UMLS CUI [1]
C0428772
abnormal global longitudinal strain (<19%, or a % decrease of ≥ 11% from baseline) prior to initiation of planned anti-her2 therapy
Description

Longitudinal strain rate.diastole.max Abnormal | Longitudinal strain rate.systole.max Abnormal | Status pre-HER2 Targeted Therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C4263402
UMLS CUI [1,2]
C0205161
UMLS CUI [2,1]
C4263410
UMLS CUI [2,2]
C0205161
UMLS CUI [3,1]
C0332152
UMLS CUI [3,2]
C0069515
UMLS CUI [3,3]
C2985566
heart rate ≥ 50 beats per minute
Description

Heart rate

Data type

boolean

Alias
UMLS CUI [1]
C0018810
sitting systolic blood pressure > 90 mmhg
Description

Sitting systolic blood pressure

Data type

boolean

Alias
UMLS CUI [1]
C1319893
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients are to be excluded from randomization for aim 2 of this study if they meet any of the following criteria:
Description

Criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
current treatment with ace-inhibitors or beta blockers
Description

Angiotensin-Converting Enzyme Inhibitors | Adrenergic beta-1 Receptor Antagonists

Data type

boolean

Alias
UMLS CUI [1]
C0003015
UMLS CUI [2]
C0304516
allergies or inability to tolerate beta blockers previously due to bradycardia, hypotension, or av block.
Description

ID.17

Data type

boolean

known history of nci ctcae (version 4.0) grade ≥ 2 symptomatic chf, myocardial infarction within 12 months prior to randomization, significant symptoms (grade ≥ 3) relating to left ventricular dysfunction, significant (moderate or severe) valvular disease, or significant cardiac arrhythmia (grade ≥ 3)
Description

ID.18

Data type

boolean

pre-menopausal women without a negative serum or urine pregnancy test within 4 weeks of starting treatment
Description

ID.19

Data type

boolean

already enrolled in a breast cancer medicine therapeutic intervention trial
Description

ID.20

Data type

boolean

Similar models

Eligibility Breast Cancer NCT02177175

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Age
Item
age ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Invasive carcinoma of breast | Neoplasm Metastasis Absent
Item
non-metastatic histologically confirmed primary invasive breast carcinoma
boolean
C0853879 (UMLS CUI [1])
C0027627 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
HER2-positive carcinoma of breast
Item
pathologically confirmed her2-positive breast cancer
boolean
C1960398 (UMLS CUI [1])
Chemotherapy Scheduled | Anthracyclines | HER2 Targeted Therapy
Item
scheduled to receive anthracycline chemotherapy followed by anti-her2 therapy at mskcc
boolean
C0392920 (UMLS CUI [1,1])
C0205539 (UMLS CUI [1,2])
C0282564 (UMLS CUI [2])
C0069515 (UMLS CUI [3,1])
C2985566 (UMLS CUI [3,2])
Informed Consent
Item
able and willing to provide informed consent
boolean
C0021430 (UMLS CUI [1])
Protocol Compliance
Item
willing and able to comply with the requirements of the protocol
boolean
C0525058 (UMLS CUI [1])
Able to swallow capsules
Item
able to swallow capsules
boolean
C2712086 (UMLS CUI [1,1])
C0006935 (UMLS CUI [1,2])
Criteria Fulfill
Item
for aim 2, all patients must meet the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Inclusion criteria Fulfill
Item
meet all inclusion criteria above
boolean
C1512693 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Left ventricular ejection fraction
Item
lvef > 50%
boolean
C0428772 (UMLS CUI [1])
Longitudinal strain rate.diastole.max Abnormal | Longitudinal strain rate.systole.max Abnormal | Status pre-HER2 Targeted Therapy
Item
abnormal global longitudinal strain (<19%, or a % decrease of ≥ 11% from baseline) prior to initiation of planned anti-her2 therapy
boolean
C4263402 (UMLS CUI [1,1])
C0205161 (UMLS CUI [1,2])
C4263410 (UMLS CUI [2,1])
C0205161 (UMLS CUI [2,2])
C0332152 (UMLS CUI [3,1])
C0069515 (UMLS CUI [3,2])
C2985566 (UMLS CUI [3,3])
Heart rate
Item
heart rate ≥ 50 beats per minute
boolean
C0018810 (UMLS CUI [1])
Sitting systolic blood pressure
Item
sitting systolic blood pressure > 90 mmhg
boolean
C1319893 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Criteria Fulfill
Item
patients are to be excluded from randomization for aim 2 of this study if they meet any of the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Angiotensin-Converting Enzyme Inhibitors | Adrenergic beta-1 Receptor Antagonists
Item
current treatment with ace-inhibitors or beta blockers
boolean
C0003015 (UMLS CUI [1])
C0304516 (UMLS CUI [2])
ID.17
Item
allergies or inability to tolerate beta blockers previously due to bradycardia, hypotension, or av block.
boolean
ID.18
Item
known history of nci ctcae (version 4.0) grade ≥ 2 symptomatic chf, myocardial infarction within 12 months prior to randomization, significant symptoms (grade ≥ 3) relating to left ventricular dysfunction, significant (moderate or severe) valvular disease, or significant cardiac arrhythmia (grade ≥ 3)
boolean
ID.19
Item
pre-menopausal women without a negative serum or urine pregnancy test within 4 weeks of starting treatment
boolean
ID.20
Item
already enrolled in a breast cancer medicine therapeutic intervention trial
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial